NCT06541730 - A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects | Biotech Hunter

Enrollment

48

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

January 30, 2025

Conditions

Overweight and Obesity

Interventions

DRUG

DA-302168S

Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.

DRUG

Placebo of DA-302168S

Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.

Trial Locations (1)

230000

The Second Affiliated Hospital of Anhui Medical University, Hefei